OUTLINE OF THE PROGRAM

VULNERABLE PATIENT

- Myocardium
- Metabolic
- Immunology
- Vascular bed vulnerability
- Primary vs. secondary prevention
- Hemostatic balance
Sunday, June 21, 2015
-Day 1-

08:00 Opening remarks: Board of directors (Prof. Serruys, Prof. Stone, Prof. van der Steen, Prof. Koenig, Prof. Lerman, Dr. García- García and Dr. van Es) – 10’

08:10 Welcome remarks: Guest director (Prof. Valentin Fuster) – 10’

08:20 Key note lectures
Moderators: Valentin Fuster and Patrick W. Serruys

08:20 What have I learned from VPM 2014? A 10,000 feet view 15’
Patrick W. Serruys (NL)

08:30 Q&A

08:35 What will you learn from VPM 2015? 15’
Valentin Fuster (USA/ES)

08:45 Q&A

08:50 Primary and secondary prevention
Moderators: Wolfgang Koenig and Jagat Narula

08:50 Primary prevention programs:
1. HRP: Role of imaging for improved risk stratification 20’
Valentin Fuster (USA/ES)

2. How low should LDLC be (i.e. <30 mg/dl)? Incorporating Trial Data Into a Hybrid Statin Algorithm for Primary Prevention 10’
Paul Ridker (US)

Q&A 30’

10:00 Coffee break

10:30 Secondary prevention programs - Chairmen: Valentin Fuster and Ira Tabas

Key note lectures
10:30 Anti-inflammatory therapy in chronic disease: challenges and opportunities 15’
Ira Tabas (US)

10:45 1. Targeting inflammation in secondary prevention – from CANTOS to CIRT studies 10’
Paul Ridker (US)

Round table on inflammation: Chairmen: Valentin Fuster and Ira Tabas; Panelists: Paul Ridker, Bart Staels, Eric Stroes and Andres Hidalgo

10:55 Discussion points:
- Inflammatory pathways that regulate the properties of plaques that precipitate acute coronary syndromes vs. those that modulate the clinical consequences of the thrombotic complications of atherosclerosis. How and where do the 2 pathways cross?
- Role of macrophages in necrotic core formation: apoptosis vs. oncosis
- Role of eosinophils in AMI
- How to assess inflammation status of a patient? Biomarkers vs. imaging
- Local (statin-loaded reconstituted HDL nanoparticle) vs. systemic anti-inflammatory therapies (i.e. metrotexate)

12:00 2. Interventional approach:
a. from CVLPRIT/PRAMI (treatment of non culprit obstructive lesions) to PROSPECT ABSORB studies (treatment of non culprit non obstructive lesions) 10'

  Gregg Stone (US)
a. local therapies to reduce plaque size and improve shear stress conditions 10'

  Patrick W. Serruys (NL)

12:20 Q&A 30'

12:50 Lunch break

Session on vascular bed vulnerability
Chairmen: Amir Lerman and Wolfgang Koenig
14:00 Coronary manifestations of fibromuscular dysplasia 10'

  Jeffrey Olin (USA)
14:10 Q&A

14:15 Venous thromboembolism as chronic inflammatory disease 10'

  Paul Ridker (USA)
14:25 Q&A

14:30 Peripheral artery disease: PARC 10'

  Jeffrey Olin (USA)
14:40 Q&A

14:45 Atherosclerotic renovascular disease 10'

  Lilach Lerman (USA)
14:55 Q&A

15:00 Discordance Between Stenosis and Ischemia: Are We Ready for New Vocabulary? 10'

  Jagat Narula (USA)
15:10 Q&A

15:15 Endothelial function assessment: implications for risk stratification 10'

  Amir Lerman (USA)
15:25 Q&A

15:25 Coffee break
16:00 Master lecture
Moderator: Wolfgang Koenig
The brain in the context of the vulnerable patient 30’
Valentin Fuster (USA)

16:30 Discussion

Session on patient vulnerability
Chairman: Javier Escaned and James Rudd
17:00 Clinical relevance of detection of significant coronary artery disease by noninvasive anatomical and functional imaging 10’
Jose Zamorano (ES)
17:10 Q&A
17:15 FFRCT vs. Multislice slice CT alone: which hemodynamics, plaque morphology, myocardium size and geometry parameters are associated with clinical events 10’
Pedro A. Gonzalvez (PT)
17:25 Q&A
17:30 What is more predictive of clinical events: angina symptoms, ischaemia tests or anatomic burden 10’
Gregg Stone (US)
17:40 Q&A
17:45 One of the highest risk vulnerable patients are those with refractory angina 10’
Marc Jollicouer (CAN)
17:55 Q&A
17:45 Interplay between lipids and inflammation in CVD patients? 10’
Eric Stroes (NL)
17:55 Q&A
17:45 In-situ biomarker assessments 10’
Plaque Tec (UK)
17:55 Q&A
18:00 Round table: James Rudd, Javier Escaned, Pedro A. Gonzalvez, Gregg Stone, Jagat Narula, Eric Stroes, Jose Zamorano and Marc Jollicoeur
Thus, how should we assess patient vulnerability?
   a. in patients without previous events
   b. in patients with previous events
   c. what does really matter in patients with refractory angina?

19:00 Closing remarks: Hector M. Garcia-Garcia
Session on surrogates for assessing vulnerability: translational research

Chairmen: Bart Staels and Borja Ibañez

08:00  Mechanisms and consequences of intraplaque haemorrhages 10’
       
       Bart Staels (BE)

08:10  Q&A

08:15  The role of progerin in atherosclerosis development: animal and human findings
       and therapeutical implications 10’
       
       Vicente Andres (ES)

08:25  Q&A

08:30  Molecular mechanism of PPARα action and its impact on lipid metabolism and
       inflammation 10’
       
       Bart Staels (BE)

08:40  Q&A

08:45  Animal studies of neoatherosclerosis (new form of VP): a growing finding in late
       stent complications events 10’
       
       Michael Joner (USA)

08:55  Q&A

09:00  Identifying biologically high-risk stents: more useful than identifying high-risk plaques? 10’
       
       Farouc Jaffer (USA)

09:10  Q&A

09:15  Translational research: how does it help to make corporal decisions on to move a drug candidate forward? 10’
       
       Benoît Tyl (FR)

09:25  Q&A

09:30  Defective efferocytosis as a cause of the necrotic core formation in VP 10’
       
       Ira Tabas (USA)

09:40  Q&A

09:45  Coffee break

Session on intravascular imaging: Part 1

Chairmen: Hector M. Garcia-Garcia and Gary Mintz

10:30  3D OCT imaging for assessment of vasa vasorum 10’
       
       Amir Lerman (USA)

10:40  Q&A

10:45  NIRS: lipid and collagen assessment 10’
       
       David Erlinge

10:55  Q&A

11:00  Endogenous and targeted NIR fluorescence to identify high-risk plaques 10’
       
       Farouc Jaffer (USA)

11:10  Q&A
11:15  Quantitative OCT tissue type imaging detects TCFA -- the Attenuating Plaque Index10’
  Gijs van Soest (NL)
11:25  Q&A
11:30  Photoacoustics 10’
  Ton van der Steen (NL)
11:40  Q&A
11:45  Advances in dual-modal OCT-based coronary plaque imaging 10’
  Farouc Jaffer (USA)
11:55  Q&A
12:00  Every intravascular imaging has major limitations: are they useful at all 15’
  Gary Mintz (USA)

12:15  Round table: Chairmen: Hector M. Garcia-Garcia and Gary Mintz; Panelists: Farouc Jaffer, Ton van der Steen and David Erlinge, Gijs Soest and Patrick W. Serruys
  When/if intravascular imaging will be routinely use for seeking vulnerable plaques: our view 45’

13:00  Lunch break

Session on non invasive imaging: Part 1
  Chairmen: Jagat Narula and James Rudd
14:00  Should We Continue to Chase Vulnerable Plaques?10’
  Jagat Narula (USA)
14:10  Q&A
14:15  PET imaging of atherosclerosis 10’
  James Rudd (UK)
14:25  Q&A
14:30  Non obstructive coronary disease is prognostically relevant but it is frequently overlooked 10’
  Pedro Gonzalvez (POR)
14:40  Q&A
14:45  PESA study: ongoing imaging findings, from ultrasound to PET/MR 20’
  Valentin Fuster (USA) / Antonio Fernández-Ortíz (SP)
14:55  Q&A
15:00  The PROMISE, SCOT HEART and FACTOR 64 studies 10’
  Udo Hofman (USA)
15:10  Round table: Chairmen: Jagat Narula and James Rudd; Panelists: Pedro Gonzalvez, Valentin Fuster and Udo Hofman
  - The role of non invasive imaging in primary and secondary prevention
16:00  Coffee break
The precision medicine session: Chiarmen: Wolfgang Koenig and Amir Lerman
16:30    The continuum of personalized cardiovascular medicine15’
          Paulus Kirchhof (UK)
16:45    Q&A
17:00    Genetic risk and CHD: Potential differences in treatment response?15’
          Heribert Schunkert (GER)
17:15    Q&A
Tuesday, June 23, 2015
- Day 3 -

Session on haemostatic balance
Chairman: Gregg Stone and Patrick W. Serruys

08:00
Balancing ischemia and bleeding risk: the bivalirudin story 10’
**Gregg Stone (NL)**

08:10
Q&A

08:15
Is there any role of point-of-care CYP2C19 genetic testing 10’
**David Erlinge (SW)**

08:25
Q&A

08:30
Antiplatelet therapy after drug-eluting stent implantation: too much focus on the stented region, vulnerable spots are located elsewhere 10’
**Roxana Mehran (USA)**

08:40
Is there any role for rivaroxaban and vorapaxar for preventing MI 10’
**Hector M. Garcia-Garcia (NL)**

08:50
Round table: Moderators: Patrick W. Serruys and Gregg Stone; Panelists: Roxana Mehran, David Erlinge, Antonio Fernández-Ortiz and Hector M. Garcia-Garcia
- Are differences in antiplatelet drugs with regards to non stented MI prevention?
- Must antiplatelet inhibitors be administered life long?
- Are all patients with known CAD candidates for antiplatelet inhibitors? Or should they be stratified?
- Are differences in NOACs with regards to non stented MI prevention?

09:20
Coffee break

Treatment opportunities for vulnerable patients/plaques
Chairman: Wolfgang Koenig and Eric Stroes

09:45
EMBRACE study 10’
**Lilach Lerman (USA)**

09:55
Q&A

10:00
Coronary liposuction during percutaneous coronary intervention: evidence by near-infrared spectroscopy that aspiration reduces culprit lesion lipid content prior to stent placement 10’
**David Erlinge (SW)**

10:10
Q&A

10:15
Lipoprotein(a): genetics, biological role, predictive value and drug interventions 10’
**Evan A Stein (US)**

10:25
Q&A

10:30
Rapamycin, Intestinal bile acid (BA) sequestration, etc. 10’
**Bart Staels (BEL)**

10:40
Q&A
Key notes lecture
10:45 Are the PCSK9 inhibitors the panacea of atherosclerosis treatment: its effects on lipid lowering and beyond 15’
   *Evan A Stein (USA)*
11:00 Q&A
11:05 Apo I Milano: phase I results and more...
   *David Kallend (CH)*
11:20 Q&A

Session on Invasive imaging update (PART II)
   *Moderators: Akiko Maehara and Evelyn Regar*
11:30 Lipid Rich Plaque trial
   *Jim Muller (USA)*
11:40 Q&A
11:45 Effects of high dose rosuvastatin in non intervened vessels of a real practice population: IBIS 3 final results
   *Patrick W. Serruys (NL)*
11:55 Q&A
12:00 Effects of high dose rosuvastatin in non intervened vessels of patients suffering from STEMI: IBIS 4 IVUS and VH results
   *Hector M. Garcia-Garcia (NL)*
12:10 Q&A
12:15 Local therapies for plaque modification: IBIS 5 preliminary observations
   *Patrick W. Serruys (NL)*
12:25 Q&A
12:30 AHEROREMO study: Lipidomics and genetics results
   *Evelyn Regar*
12:40 Q&A
12:45 PROSPECT II: where are we?
   *Akiko Maehara*
12:55 Q&A
13:00 Lunch break

Session on surrogates for assessing vulnerability: translational research part II
   *Moderators: Jacob Fog Bentzon and Robert Wilensky*
14:00 Gene modified minipigs: possibilities and limitations
   *Jacob Fog Bentzon (DN)*
14:10 Q&A
14:15 Porcine models of accelerated coronary atherosclerosis
   *Robert Wilensky (USA)*
14:25 Q&A

14:30 Effect of the Absorb Bioresorbable Vascular Scaffold (BVS) in a Familial Hypercholesterolemic Swine: main results
*Evelyn Regar (NL)*

14:40 Discussion

15:00 Coffee break

15:30 Closing session - My vulnerable patient trial design: Gregg Stone and Patrick W. Serruys

15:30 My proposal: using sophisticated statistics and study design methods 10’
*Marc Jollicoeur (CAN)*

15:40 Q&A

15:45 What would it take to prove the promise of local treatment of VP?
*Gregg Stone (USA)*

15:55 Q&A

Debate
16:05 There is a shift in paradigm, times are moved away from VP 10’
*Valentin Fuster (USA)*

16:15 No so fast, it is all about VPs 10’
*Jim Muller (USA)*

16:25 Discussion

17:00 Closing remarks:
Guest director: Valentin Fuster
Board of directors (Prof. Serruys, Prof. Stone, Prof. van der Steen, Prof. Koenig, Prof. Lerman, Dr. García and Dr. van Es)